Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 152,953 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Condition Clear all
Terminated Phase 2 Interventional

Efficacy and Safety Study of Cetuximab or Cetuximab Plus Docetaxel to Treat Prostate Cancer Before Prostatectomy

NCT00448097
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
cetuximab, docetaxel
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

NCT01438710
View directory record Official record
Conditions
Renal Failure, Tremors
Interventions
Prograf, LCP-Tacro
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

NCT04411810
View directory record Official record
Conditions
Skin Cancer
Interventions
Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra
Device · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 90 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional

Automated Diabetes Registry Tools to Enhance Patient Self-Management and Provider Performance Feedback

NCT00827710
View directory record Official record
Conditions
Diabetes
Interventions
point of care patient report cards, Provider performance report card
Behavioral
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years to 75 Years
Enrollment
5,457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2012 · Synced Oct 29, 2026, 11:40 AM EDT
Terminated Phase 3 Interventional

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

NCT00054210
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
34
States / cities
Birmingham, Alabama • Hoover, Alabama • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 29, 2026, 11:40 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Mechanistic Insights From Bronchoscopy Airway Samples

NCT06105710
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Not yet recruiting Phase 3 Interventional

Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis

NCT07520110
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Metformin, Matching Placebo
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Aurora, Colorado • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine

NCT03755713
View directory record Official record
Conditions
Peanut Allergy
Interventions
ASP0892, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Little Rock, Arkansas • Mountain View, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Recruiting Not applicable Interventional

Ventricular Tachycardia Mechanisms

NCT05478213
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Monophasic Action Potential (MAP) Catheter
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional Results available

Audio-Visual Relaxation Technology for Pediatric Amplified Musculoskeletal Pain Syndrome

NCT03762213
View directory record Official record
Conditions
Amplified Musculoskeletal Pain Syndrome, Reflex Sympathetic Dystrophy, Complex Regional Pain Syndromes
Interventions
Oculus GO VR HMD, application Happy Place (© Mimerse), iPad, application Happy Place (© Mimerse)
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 29, 2026, 11:40 AM EDT
Active, not recruiting Phase 3 Interventional

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913
View directory record Official record
Conditions
Gastrointestinal Neoplasms, Esophagogastric Junction
Interventions
Durvalumab, FLOT chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 200 Years
Enrollment
957 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
16
States / cities
Duarte, California • Los Angeles, California • Sylmar, California + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1Phase 2 Interventional

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

NCT00572013
View directory record Official record
Conditions
Lymphoma
Interventions
Rituxan, BEAM, Autologous stem cell transplant
Drug · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 29, 2026, 11:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

NCT02498613
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer AJCC v7, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage III Lung Small Cell Carcinoma AJCC v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Small Cell Carcinoma AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Small Cell Carcinoma AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Small Cell Carcinoma AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Pancreatic Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions
18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis, Olaparib, Positron Emission Tomography
Other · Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
14
States / cities
La Jolla, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exercise Training for Patients With Poor Leg Circulation

NCT00118560
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Intermittent Claudication
Interventions
Physical exercise, Physical walking
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
West Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2011 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 4 Interventional

IV Methadone Vs EXPAREL Erector Spinae Plane Blockade in Pediatric Subjects Undergoing Idiopathic Scoliosis Correction

NCT05730920
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis, Juvenile Idiopathic Scoliosis
Interventions
Methadone, Liposomal bupivacaine (LB, Exparel)
Drug
Lead sponsor
Dr. Casey Stondell, MD
Other
Eligibility
11 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Withdrawn No phase listed Observational

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

NCT03296124
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 29, 2026, 11:40 AM EDT
Completed No phase listed Observational Results available

Outcomes After Hypotensive Neuraxial Anesthesia in Total Hip Arthroplasty

NCT03973320
View directory record Official record
Conditions
Total Hip Arthroplasty, Primary Total Hip Arthroplasty, Hypotension, Database
Interventions
Chart Review
Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years and older
Enrollment
11,292 participants
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420
View directory record Official record
Conditions
IBD (Inflammatory Bowel Disease), IBS - Irritable Bowel Syndrome, Crohn Disease (CD), UC - Ulcerative Colitis
Interventions
ALPCO Calprotectin CLIA
Device
Lead sponsor
American Laboratory Products Company
Industry
Eligibility
22 Years and older
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Salem, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
No Longer Available No phase listed Expanded access

Therasphere for Unresectable Primary or Secondary Liver Neoplasia

NCT02960620
View directory record Official record
Conditions
Liver Cancer, Liver Neoplasms, HepatoCellular Carcinoma
Interventions
TheraSphere Treatment
Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 29, 2026, 11:40 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension of Prior TERMS Study to Treat Relapsing Forms of Multiple Sclerosis

NCT00595920
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
Interventions
Tovaxin
Biological
Lead sponsor
Opexa Therapeutics, Inc.
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
27
States / cities
Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional

Use of a Radiolucent Pad to Reduce Mammography Among African Americans

NCT00594282
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiolucent cushion
Device
Lead sponsor
University of Kansas
Other
Eligibility
40 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Oct 29, 2026, 11:40 AM EDT
Not listed Phase 1Phase 2 Interventional

Determining the Safety of L-serine in ALS

NCT01835782
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
L-Serine
Drug
Lead sponsor
Phoenix Neurological Associates, LTD
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
2
States / cities
Phoenix, Arizona • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 29, 2026, 11:40 AM EDT
Not listed Not applicable Interventional

Emotion Regulation Interventions for Preventing Collegiate Escalations in Drinking

NCT04492982
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Yoga, Distress Tolerance
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
Not listed
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Storrs, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 29, 2026, 11:40 AM EDT
Recruiting Not applicable Interventional

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

NCT05961982
View directory record Official record
Conditions
Pancreatic Neoplasm
Interventions
Chemical Ablation, Computed Tomography, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Endoscopic Ultrasound-Guided Radiofrequency Ablation, Magnetic Resonance Cholangiopancreatography, Magnetic Resonance Imaging
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 29, 2026, 11:40 AM EDT